Glenn Jaffe, MD
Enriched profileRobert Machemer M.D. Distinguished Professor of Ophthalmology; Chief, Division of Retinal Ophthalmology (Vitreoretinal Disease) · Duke University Eye Center
Glenn Jaffe is Robert Machemer M.D. Distinguished Professor of Ophthalmology; Chief, Division of Retinal Ophthalmology (Vitreoretinal Disease) at Duke University Eye Center. ClinicalTrials.gov lists 8 registered studies with this person as an investigator.
Data verified 17 Aug 2026
Overview
Updated 2 Sept 2026
Glenn Jaffe, M.D., is Robert Machemer M.D. Distinguished Professor of Ophthalmology at Duke University Eye Center, Department of Ophthalmology, Duke University School of Medicine. The public record shows 20 publications with 732 citations (h-index 14), centered on Dry Eye / Uveitis, Uveitis, Retinal Vein Occlusion. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 17 companies, 6 NIH-funded awards (1989–2026).
- Top research focus: Dry Eye / Uveitis
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 17 companies
Generated from the cited public record · current as of 2 Sept 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 2 Sept 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
Sponsor: EyePoint Pharmaceuticals, Inc.
Industry payments
Updated 2 Sept 2026
17 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Ocular Therapeutix, Inc.Program year20251 payment
- Apellis Pharmaceuticals, Inc.Program year20251 payment
- ANI Pharmaceuticals, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
59.8%Corticosteroid27.2%Prednisolone Acetate100%Part D≥98 patientsCarbonic Anhydrase Inhibitor18.1%Dorzolamide-Timolol85%Dorzolamide Hcl15%Part D≥55 patientsMusculoskeletal
25.2%Cyclooxygenase Inhibitor25.2%Ketorolac Tromethamine100%Part D≥88 patientsCardiovascular
8.1%Beta blocker8.1%Timolol Maleate100%Part D≥28 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 2 Sept 2026
6 NIH research awards on record, funded 1989–2026 per NIH RePORTER. The latest:
- NAC Attack, a phase-3, multicenter, randomized, placebo-controlled trial with retinitis pigmentosa: OCT Reading Center
Duke University
FY2026$265,370UG1EY033287 - NAC Attack, a phase-3, multicenter, randomized, placebo-controlled trial with retinitis pigmentosa: OCT Reading Center
Duke University
FY2025$256,633UG1EY033287 - NAC Attack, a phase-3, multicenter, randomized, placebo-controlled trial with retinitis pigmentosa: OCT Reading Center
Duke University
FY2024$259,193UG1EY033287
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Online presence
Updated 2 Sept 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Google Scholar
scholar.google.com/citations
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholar.google.com ↗ - ResearchGate
researchgate.net/profile/Glenn-Jaffe
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/DukeEye/posts/glenn-jaffe-md-retina-specialist-at-duke-eye-center-led-one-of-two-clinical-stud/10154086135602830
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Other
retinaroundup.com/2018/07/05/how-glenn-jaffe-approaches-uveitis-surgery
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →retinaroundup.com ↗ - Other
asrs.org/find-a-specialist/profile/994/Glenn-J-Jaffe
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →asrs.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 2 Sept 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- M.D.
University of California, San Francisco, School of Medicine (1983) -- corroborates NPI-registry credential M.D.
1983verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu ↗ - Board certified
American Board of Ophthalmology (Ophthalmology)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗
Editorial & leadership roles
journal and society appointments- Editorial Board member
Ocular Surgery News (Retina/Vitreous section)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com ↗ - Editorial Board member
Retina (journal)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lmri.net ↗ - Editorial Board member
Current Opinion in Ophthalmology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lmri.net ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukeeyecenter.duke.edu ↗
- Named among the top basic medicine scientists in the United States
4th edition of Research.com's ranking of leading scholars in Medicine
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukeeyecenter.duke.edu ↗ - ASRS Presidential Award (2024)
for contributions to the scientific programs of the annual meeting
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukeeyecenter.duke.edu ↗
Secondary affiliations
appointments beyond the home institution- Scientific Advisory Board
EyePoint Pharmaceuticals
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →eyepoint.bio ↗ - Medical Advisory Board
Neurotech Pharmaceuticals
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →neurotechpharmaceuticals.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →retinaroundup.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.